Delving into the Latest Updates on Interferon alpha 5(Biotecnol Ltd.) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms-

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Infectious Diseases

Originator Organization

Biotecnol Ltd.Startup

Active Organization-

Inactive Organization

Biotecnol Ltd.Startup

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

TO THEEDITOR: In 1984, Sokal et al 1 developed a scoring system to predict the outcome of patients with chronic myeloid leukemia (CML). The scoring system rapidly gained popularity and has remained until now the most widely accepted method for assessing prognosisforpatientswithCML.AlthoughtheSokalscorewasdeveloped for patients with nonblastic disease who were treated with hydroxyureaorbusulfan,italsoprovedusefulforpredictingthesurvival of patients treated with interferon 2 and can predict the outcome for patients treated with imatinib. 3,4 Interestingly, it also predicts the outcome for patients who receive imatinib after experiencing treatment failure with interferon 5 and for patients who receive secondgeneration tyrosine kinase inhibitors after experiencing treatment failurewithimatinib. 6 TheconsistentvalueoftheSokalscoringsystem

100 Deals associated with Interferon alpha 5(Biotecnol Ltd.)

Login to view more data